Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder

International Journal of Neuropsychopharmacology

Volumn 11, Issue 1, 2008, Pages 35-48

  Lazar, Andreas ^a,f   Walitza, Susanne ^b   Jetter, Alexander ^a   Gerlach, Manfred ^b   Warnke, Andreas ^b   Herpertz Dahlmann, Beate ^c   Gründemann, Dirk ^a   Grimberg, Gundula ^a   Schulz, Eberhard ^d   Remschmidt, Helmut ^e   Wewetzer, Christoph ^b   Schömig, Edgar ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Genetic polymorphism; Norepinephrine; Obsessive compulsive disorder; SLC22A3

Indexed keywords

COMPLEMENTARY DNA; LUCIFERASE; NORADRENALIN;

ADOLESCENT; ALLELE; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EMT GENE; FEMALE; GENE; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENE SEGREGATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGE OF ONSET; ALLELES; ANIMALS; CASE-CONTROL STUDIES; CELL LINE; CHILD; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTRONS; LUCIFERASES; MALE; MUTATION; OBSESSIVE-COMPULSIVE DISORDER; ORGANIC CATION TRANSPORT PROTEINS; PEDIGREE; PLASMIDS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SPECIES SPECIFICITY; TOURETTE SYNDROME;

EID: 38149024853     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007742     Document Type: Article

References (59)

1. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM (1999). Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. British Journal of Clinical Pharmacology 48, 345-354.
2. Albert U, Bergesio C, Pessina E, Maina G, Bogetto F (2002). Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy. Panminerva Medica 44, 83-91.
3. Alsobrook 2nd JP, Zohar AH, Leboyer M, Chabane N, Ebstein RP, Pauls DL (2002). Association between the COMT locus and obsessive-compulsive disorder in females but not males. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 114, 116-120.
4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn). Washington DC: American Psychiatric Association.
5. APA (2000). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn, text revision). Washington DC: American Psychiatric Association.
6. Azzam A, Mathews CA (2003). Meta-analysis of the association between the catecholamine-O-methyltransferase gene and obsessive-compulsive disorder. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 123, 64-69.
7. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH (1997). Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. American Journal of Psychiatry 154, 1293-1295.
8. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Molecular Pharmacology 53, 649-655.
9. Benkelfat C, Mefford IN, Masters CF, Nordahl TE, King AC, Cohen RM, Murphy DL (1991). Plasma catecholamines and their metabolites in obsessive-compulsive disorder. Psychiatry Research 37, 321-331.
10. Billett EA, Richter MA, King N, Heils A, Lesch KP, Kennedy JL (1997). Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Molecular Psychiatry 2, 403-406.
11. Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A, Perini G, Carraro C, Gava F (1997). Noradrenergic receptor sensitivity in obsessive compulsive disorder : II. Cortisol response to acute clonidine administration. Psychiatry Research 69, 163-168.
12. Camarena B, Rinetti G, Cruz C, Hernandez S, de la Fuente JR, Nicolini H (2001). Association study of the serotonin transporter gene polymorphism in obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 4, 269-272.
13. Carey G, Gottesmann II (1981). Defining cases by genetic criteria. In : Wing JK, Bebbington P, Robins LW (Eds.), What is Case? (pp. 29-41). London: Grant McIntyre.
14. Dell'Osso B, Nestadt G, Allen A, Hollander E (2006). Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder : a critical review. Journal of Clinical Psychiatry 67, 600-610.
15. den Dunnen JT, Antonarakis SE (2001). Nomenclature for the description of human sequence variations. Human Genetics 109, 121-124.
16. Denys D, van Megen HJ, van der Wee N, Westenberg HG (2004). A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Journal of Clinical Psychiatry 65, 37-43.
17. Dilling H, Mombour W, Schmidt MH, Schulte-Markwort (1994). Internationale Klassifikation psychischer Störungen (ICD-10). Bern: Huber.
18. Dong XP, Stubenrauch F, Beyer-Finkler E, Pfister H (1994). Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. International Journal of Cancer 58, 803-808.
19. Eisenhofer G (2001). The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacology and Therapeutics 91, 35-62.
20. Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D (1998). 5-HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder. Lancet 351, 1785-1786.
21. Frisch A, Michaelovsky E, Rockah R, Amir I, Hermesh H, Laor N, Fuchs C, Zohar J, Lerer B, Buniak SF, et al. (2000). Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. European Neuropsychopharmacology 10, 205-209.
22. Geller DA, Biederman J, Faraone SV, Bellordre CA, Kim GS, Hagermoser L, Cradock K, Frazier J, Coffey BJ (2001). Disentangling chronological age from age of onset in children and adolescents with obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 4, 169-178.
23. Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV (2003). Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. American Journal of Psychiatry 160, 1919-1928.
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-1011.
25. Gordon D, Heath SC, Liu X, Ott J (2001). A transmission/ disequilibrium test that allows for genotyping errors in the analysis of single-nucleotide polymorphism data. American Journal of Human Genetics 69, 371-380.
26. Gründemann D, Koschker AC, Haag C, Honold C, Zimmermann T, Schömig E (2002). Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells. British Journal of Pharmacology 137, 910-918.
27. Gründemann D, Schechinger B, Rappold GA, Schömig E (1998). Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nature Neuroscience 1, 349-351.
28. Gründemann D, Schömig E (2000). Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Human Genetics 106, 627-635.
29. Haag C, Berkels R, Gründemann D, Lazar A, Taubert D, Schömig E (2004). The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. Journal of Neurochemistry 88, 291-297.
30. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M (2003). Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. American Journal of Human Genetics 73, 370-376.
31. Hand I, Büttner-Westphal H (1991). Die Yale-Brown Obsessive Compulsive Scale (YBOCS): Ein halbstrukturiertes Interview zur Beurteilung des Schweregrades von Denk- und Handlungszwängen. Verhaltenstherapie 1, 223-225.
32. Hanna GL, Yuwiler A, Coates JK (1995). Whole blood serotonin and disruptive behaviors in juvenile obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 34, 28-35.
33. Hebebrand J, Klug B, Fimmers R, Seuchter SA, Wettke-Schafer R, Deget F, Camps A, Lisch S, Hebebrand K, von Gontard A, et al. (1997). Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. Journal of Psychiatric Research 31, 519-530.
34. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB (2003). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Journal of Clinical Psychiatry 64, 1113-1121.
35. Hollander E, DeCaria C, Nitescu A, Cooper T, Stover B, Gully R, Klein DF, Liebowitz MR (1991). Noradrenergic function in obsessive-compulsive disorder : behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Research 37, 161-177.
36. Jans T, Wewetzer C, Klampfl K, Schulz E, Herpertz-Dahlmann B, Remschmidt H, Warnke A (2007). Phenomenology and co-morbidity of childhood onset obsessive compulsive disorder [in German]. Zeitschrift für Kinder- und Jugendpsychiatrie 35, 41-50.
37. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, Gogos JA (1997). Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proceedings of the National Academy of Sciences USA 94, 4572-4575.
38. Karayiorgou M, Sobin C, Blundell ML, Galke BL, Malinova L, Goldberg P, Ott J, Gogos JA (1999). Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biological Psychiatry 45, 1178-1189.
39. King RA, Scahill L (1995). In : Robertson MM, Eapen (Eds.), Movement and Allied Disorders in Childhood (pp. 42-56). New York: John Wiley and Sons.
40. Lazar A, Gründemann D, Berkels R, Taubert D, Zimmermann T, Schömig E (2003). Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). Journal of Human Genetics 48, 226-230.
41. McDougle CJ, Barr LC, Goodman WK, Price LH (1999). Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24, 1-24.
42. Millet B, Chabane N, Delorme R, Leboyer M, Leroy S, Poirier MF, Bourdel MC, Mouren-Simeoni MC, Rouillon F, Loo H, Krebs MO (2003). Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 116, 55-59.
43. Moeller HJ (2000). Are all antidepressants the same? Journal of Clinical Psychiatry 61, (Suppl. 6), 24-28.
44. Mossner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, Bogusch L, Remschmidt H, Simons M, Herpertz-Dahlmann B, et al. (2006). Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 9, 437-442.
45. Nemeroff CB, Owens MJ (2003). Reviews of Physiology, Biochemistry and Pharmacology 150, 36-90.
46. Nemeroff CB, Owens MJ (2004). Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectrums 9, 23-31.
47. Nestadt G, Samuels J, Riddle M, Bienvenu 3rd OJ, Liang KY, LaBuda M, Walkup J, Grados M, Hoehn-Saric R (2000). A family study of obsessive-compulsive disorder. Archives of General Psychiatry 57, 358-363.
48. Pauls DL, Alsobrook 2nd JP, Goodman W, Rasmussen S, Leckman JF (1995). A family study of obsessive-compulsive disorder. American Journal of Psychiatry 152, 76-84.
49. Pauls DL, Hurst CR (1991). Schedule for Tourette and other Behavioral Syndromes. New Haven: Yale University School of Medicine.
50. Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E (1999). Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 38, 1180-1185.
51. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF (1997). Children's Yale-Brown Obsessive Compulsive Scale : reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 36, 844-852.
52. Schildkraut JJ, Mooney JJ (2004). Toward a rapidly acting antidepressant: the normetanephrine and extraneuronal monoamine transporter (uptake 2) hypothesis. American Journal of Psychiatry 161, 909-911.
53. Schömig E, Russ H, Staudt K, Martel F, Gliese M, Gründemann D (1998). The extraneuronal monoamine transporter exists in human central nervous system glia. Advances in Pharmacology 42, 356-359.
54. Shugart YY, Samuels J, Willour VL, Grados MA, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, Wang Y, et al. (2006). Genomewide linkage scan for obsessive-compulsive disorder : evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. Molecular Psychiatry 11, 763-770.
55. Unnewehr S (1995). Diagnosis of psychiatric disorders in children and adolescents using structured interviews [in German]. Zeitschrift für Kinder- und Jugendpsychiatrie 23, 121-132.
56. Walitza S, Wewetzer C, Warnke A, Gerlach M, Geller F, Gerber G, Gorg T, Herpertz-Dahlmann B, Schulz E, Remschmidt H, et al. (2002). 5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders. Molecular Psychiatry 7, 1054-1057.
57. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V (1998). Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. Journal of Biological Chemistry 273, 32776-32786.
58. Zhao JH, Lissarrague S, Essioux L, Sham PC (2002). GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics 18, 1694-1695.
59. Zohar J, Chopra M, Sasson Y, Amiaz R, Amital D (2000). Obsessive compulsive disorder : serotonin and beyond. World Journal of Biological Psychiatry 1, 92-100.